Stock Details
BHC is Bausch Health Companies Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 6.39$. Average daily volumn in 3 months 8.91M. Market cap 2.71B



Stock symbol : BHC. Exchange : NYSE. Currency : USD
Lastest price : 7.54$. Total volume : 5.17M. Market state POST
Click reload if you want to check the lastest price on market!!!

Bausch Health Companies Inc. (BHC)
Last Price
7.54$
Change
0.51
Volume
5.17M

Previous Close7.03
Open7.25
Day Range7.21-7.56
Bid7.53 x 1.4k
Ask7.54 x 1.3k
Volume5.17M
Average Volume8.91M
Market Cap2.71B
Beta1.21
52 Week Range4.00-29.31
Trailing P/E53.86
Foward P/E1.29
Dividend (Yield %)N/A
Ex-Dividend Date2010-11-10



Financial Details


According to Bausch Health Companies Inc.'s financial reports the company's revenue in 2021 were 8.43B an increase(0%) over the years 2020 revenue that were of 8.03B. In 2021 the company's total earnings were -948M while total earnings in 2020 were -560M( +69.29%).


Loading ...



Organization

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical... , and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Market Cap:
2.71B
Revenue:
8.43B
Total Assets:
29.2B
Total Cash:
582M


News about "Bausch Health Companies Inc."

bausch-health-announces-final-results-and-expiration-of-exchange-offers-and-consent-solicitations-image

Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations

Source from : Business Insider - 6 days ago

Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the final results and expiration of its previously announced offers (the "Exchange Offers") to exchange the existing senior ...See details»


bausch-health-companies-inc-nysebhc-stake-decreased-by-mirae-asset-global-investments-co-ltd-image

Bausch Health Companies Inc. (NYSE:BHC) Stake Decreased by Mirae Asset Global Investments Co. Ltd.

Source from : Defense World - 5 days ago

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 13.6% in the first quarter, according to its most recent 13F filing with the ...See details»


bausch-health-companies-inc-tsebhc-to-post-q3-2022-earnings-of-134-per-share-zacks-research-forecasts-image

Bausch Health Companies Inc. (TSE:BHC) to Post Q3 2022 Earnings of $1.34 Per Share, Zacks Research Forecasts

Source from : Defense World - 11 days ago

Analysts at Zacks Research lifted their Q3 2022 EPS estimates for shares of Bausch Health Companies in a report released on Tuesday, September 20th. Zacks Research analyst E. Bagri now expects that ...See details»


bausch-health-long-term-need-to-place-stops-for-protection-image

Bausch Health: Long-Term Need To Place Stops For Protection

Source from : Seeking Alpha - 6 days ago

Bausch Health's long-term support halted the recent decline but another foray may be on the cards. Click here to find out why I'm bearish on BHC stock.See details»


bausch-health-companies-equity-stub-would-benefit-from-ambitious-spinoff-image

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Source from : Seeking Alpha - 13 days ago

Bausch Health is in the process of spinning off its 90% stake in Bausch + Lomb to shareholders. Click to read why the spinoff ultimately seems achievable to me.See details»


8-K: Bausch Health Companies Inc.

Source from : MarketWatch - 1 month ago

Item 8.01 Other Events. On August 22, 2022, Bausch Health Companies Inc. (the "Company") issued a press release, furnished herewith as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits.See details»


Great week for Bausch Health Companies Inc. (NYSE:BHC) institutional investors after losing 74% over the previous year

Source from : AOL - 23 days ago

If you want to know who really controls Bausch Health Companies Inc. (NYSE:BHC), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the ...See details»


Share Price

Source from : Forbes - 15 days ago

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products.See details»


Bausch Health Cos. Inc.

Source from : Wall Street Journal - 19 days ago

1 Day BHC -3.40% DJIA -0.45% S&P Mid Cap 400 -1.35% Health Care/Life Sciences 0.34% Richard Charles Mulligan Director Bausch Health Cos., Inc., Biogen, Inc., Kadmon Pharmaceuticals LLC, Biogen ...See details»


bausch-health-and-glenmark-announce-the-approval-of-ryaltris-in-canada-image

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

Source from : Yahoo - 11 days ago

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), are pleased to announce that RYALTRIS® ...See details»


Why Bausch Health Stock Is Jumping Today

Source from : Nasdaq - 20 days ago

Shares of Bausch Health Company (NYSE: BHC) were jumping 4.4% at 10:54 a.m. ET on Wednesday after rising as much as 11.8% earlier in the day. The gain came after the company announced results so ...See details»


Bausch Health, Glenmark Specialty Say Health Canada Approves RYALTRIS

Source from : Business Insider - 11 days ago

Bausch Health Companies Inc. (BHC, BHC.TO) and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., announced ...See details»


contact-lens-solutions-market-to-record-a-cagr-of-318-bausch-health-co-inc-and-clear-conscience-llc-among-key-vendors-technavio-image

Contact Lens Solutions Market to Record a CAGR of 3.18%, Bausch Health Co Inc and CLEAR CONSCIENCE LLC Among Key Vendors - Technavio

Source from : YAHOO!Finance - 5 days ago

The contact lens solutions market size is expected to grow by USD 398.57 million from 2021 to 2026. Technavio's latest report estimates that the growth momentum of the market will accelerate at a CAGR ...See details»


Bausch Health Companies Inc. (BHC)

Source from : Yahoo Finance - 6 days ago

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo ...See details»